Apr 18, 2023 • 8:00 am EDT Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target
Apr 17, 2023 • 8:30 am EDT Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting
Mar 14, 2023 • 4:35 pm EDT Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting
Mar 7, 2023 • 8:00 am EST Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
Mar 6, 2023 • 8:00 am EST Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA
Mar 2, 2023 • 8:00 am EST Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 13, 2023 • 6:55 am EST Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)
Nov 10, 2022 • 9:05 am EST Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Nov 8, 2022 • 8:05 am EST Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Oct 14, 2022 • 8:05 am EDT Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting